

4.0.03 DOC Cmte minutes

Lung cancer Committee meeting

Date: 04/04/2018

Location: NICE offices Manchester

Minutes: Final



Committee members present:	
Gary McVeigh (GM) (Chair)	Present for all
Shahzeena Aslam (SA)	Present for all
Lynn Campbell (LC)	Present for all
Jesme Fox (JF)	Present for all
Tom Haswell (TH)	Present for all
Sue Maughn (SM)	Present for all
Andrea McIver (AM)	Present for all
Rhiannon Walters-Davies (RW)	Present for all
Douglas West (DW)	From partway through item 3
Nigel Westwood (NWW)	Present for all
Clifford Wyn Jones (CW)	Present for all

In attendance:		
Sohaib Ashraf (SAS)	NICE – Technical Analyst Health Economics	Present for all
Rupert Franklin (RF)	NICE – Commissioning Manager	Present for all
Thomas Jarret (TJ)	NICE – Technical Analyst	Present for all
Ross Maconachie (RM)	NICE – Technical Advisor Health Economics	Present for all
Toby Mercer (TM)	NICE – Technical Analyst	Present for all
Caroline Mulvihill (CM)	NICE – Technical Advisor	Present for all
Adam O’Keefe	NICE – Project Manager	Present until partway through item 4, and from item 9

4.0.03 DOC Cmte minutes

Observers:	
Catrin Austin	NICE – Technical Analyst – from item 6

Apologies:	
Elaine Borg	Committee member
Sujal Desai	Committee member
Vonda Murray	NICE – Project Manager
Neal Navani	Committee member
Sue Spiers	NICE – Associate Director Guideline Updates Team

<p>Item 1</p> <ul style="list-style-type: none"> • Welcome • Objectives • Declarations of interest • Minutes of the last meeting

<p>Item 1</p> <p>The Chair welcomed the Committee members, and attendees to the 5th committee meeting on lung cancer.</p> <p>The objectives of the meeting, were outlined by the Chair. The minutes were reviewed from Gcomm 4; Monday 26th and Tuesday 27th February 2018. The minutes were agreed to be an accurate record.</p> <p>The DOI register was made available to the Chair, and committee. The Chair reviewed the DOI register, 1 new declarations was made, and this is noted below. The DOI's were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.</p> <table border="1" data-bbox="188 1534 1401 1767"> <thead> <tr> <th>Attendee</th> <th>Declaration</th> <th>Action</th> </tr> </thead> <tbody> <tr> <td>Shahzeena Aslam</td> <td>Attended evening meeting (7/3/18) sponsored by BMS with food in Cambridge exploring clinical cases of lung cancer treated with nivolumab</td> <td>No action other than the process of open declaration</td> </tr> </tbody> </table>	Attendee	Declaration	Action	Shahzeena Aslam	Attended evening meeting (7/3/18) sponsored by BMS with food in Cambridge exploring clinical cases of lung cancer treated with nivolumab	No action other than the process of open declaration
Attendee	Declaration	Action				
Shahzeena Aslam	Attended evening meeting (7/3/18) sponsored by BMS with food in Cambridge exploring clinical cases of lung cancer treated with nivolumab	No action other than the process of open declaration				

<p>Item 2</p> <p>Lay members slot</p>
--

<p>Item 2</p> <p>Lay members given the opportunity to ask questions of NICE staff relating to the review questions.</p>
--

4.0.03 DOC Cmte minutes

<p>Item 3 Clinical presentation (background to RQ 3.4)</p>
<p>Item 3 SA provided a clinical introduction on, chemoradiotherapy regimen for people with limited-stage small cell lung cancer. The Chair thanked SA for her presentation.</p>
<p>Item 4 3.4 What is the most clinically and cost-effective regimen of chemoradiotherapy for people with limited-stage SCLC?</p> <ul style="list-style-type: none">• Presentation of clinical evidence• Agree recommendations
<p>Item 4 TJ provided a summary of the search protocol, including the inclusion and exclusion criteria. The comparisons used in the evidence review were explained. TJ provided an overview of the evidence for; what is the most clinically and cost-effective regimen of chemoradiotherapy for people with limited-stage small cell lung cancer. The committee discussed the evidence, reviewed and updated recommendations accordingly.</p>
<p>Item 5 RQ3.3 What is the clinical and cost effectiveness of the following systemic anti-cancer therapy regimens for treating NSCLC:</p> <ul style="list-style-type: none">• platinum combinations compared with non-platinum combinations in people with advanced NSCLC (stage III or IV)• non-platinum monotherapy compared with non-platinum combinations in people with advanced NSCLC (stage III or IV) who cannot tolerate platinum combinations• Algorithm presentation
<p>Item 5 CM presented an algorithm that was created for systemic anti- therapy regimens for treating advanced NSCLC. The committee discussed the algorithm, and suggested changes.</p>
<p>Item 6 <ul style="list-style-type: none">• Clinical presentation (background to RQ 3.1)</p>
<p>Item 6 DW provided a clinical introduction on, chemotherapy, radiotherapy and surgery (alone or in combination) for the treatment for N2 stage non-small cell lung cancer.</p>

4.0.03 DOC Cmte minutes

The Chair thanked DW for his presentation.

Item 7

3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?

- Presentation of clinical evidence
- Update on health economic modelling and evidence synthesis

Item 7

TM provided an overview of the agreed protocol, including the inclusion and exclusion criteria. Details were provided on the outcome of the search and sift process. The evidence was presented to the committee on, the clinical effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage non-small cell lung cancer.

RM provided an update on the health economic modelling and evidence synthesis cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage non-small cell lung cancer.

The committee discussed the evidence presented, and asked RM and TM, questions. The committee reviewed and updated the recommendations accordingly.

Item 8

1.3 What is the clinical and cost effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to radical therapy with curative intent?

- Update on health economic modelling

Item 8

RM provided an update on the health economic modelling for cost effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to radical therapy with curative intent.

Item 9

- AOB

Item 9

- No other business to discuss

Item 10

- Summary and next steps

Item 10

The Chair thanked the committee for their hard work and contribution. The next committee meeting is GComm 6, Wednesday 16th May 2018, to be held at the NICE

4.0.03 DOC Cmte minutes

Manchester offices.

Date of next meeting: Wednesday 16th May 2018

Location of next meeting: NICE Offices – Manchester